Recent developments in migraine

The Lancet

Volumn 372, Issue 9647, 2008, Pages 1369-1371

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; NAPROXEN; OLCEGEPANT; OXCARBAZEPINE; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; TOPIRAMATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILIAL HEMIPLEGIC MIGRAINE; HEART INFARCTION; HUMAN; MIGRAINE; MIGRAINE AURA; NEBULIZATION; PATENT FORAMEN OVALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPREADING CORTICAL DEPRESSION; UNSPECIFIED SIDE EFFECT;

EID: 53749083431     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61569-X     Document Type: Note

References (16)

1. Lipton R.B., Diamond M., Freitag F., Bigal M., Stewart W.F., and Reed M.L. Migraine prevention patterns in a community sample: results from the American migraine prevalence and prevention (AMPP) study. Headache 45 (2005) 792-793 (abstr).
2. Silberstein S.D. Migraine. Lancet 363 (2004) 381-391
3. Kurth T., Schurks M., Logroscino G., Gaziano J.M., and Buring J.E. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337 (2008) a636
4. Kurth T., Gaziano J.M., Cook N.R., et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med 167 (2007) 795-801
5. Scher A.I., Terwindt G.M., Picavet H.S., Verschuren W.M., Ferrari M.D., and Launer L.J. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64 (2005) 614-620
6. Dowson A., Mullen M.J., Peatfield R., et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117 (2008) 1397-1404
7. Vanmolkot K.R., Babini E., de Vries B., et al. The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Hum Mutat 28 (2007) 522
8. Ayata C., Jin H., Kudo C., Dalkara T., and Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59 (2006) 652-661
9. Schoonman G.G., van der Grond J., Kortmann C., van der Geest R.J., Terwindt G.M., and Ferrari M.D. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 10 (2008) 2192-2200
10. Matchar D.B., Harpole L., Samsa G.P., et al. The headache management trial: a randomized study of coordinated care. Headache (2008) 10.1111/j.1526-4610.2007.01148.x published online June 10.
11. Silberstein S.D., Mannix L.K., Goldstein J., et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 71 (2008) 114-121
12. Diener H.C., Agosti R., Allais G., et al., for the TOPMAT-MIG-303 Investigators Group. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6 (2007) 1054-1062
13. Silberstein S., Saper J., Berenson F., Somogyi M., McCague K., and D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 70 (2008) 548-555
14. Doods H., Arndt K., Rudolf K., and Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 28 (2007) 580-587
15. Ho T.W., Mannix L.K., Fan X., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70 (2008) 1304-1312
16. Ho T.W., Ferrari M., Dodick D.W., et al. Acute anti-migraine efficacy and tolerability of the novel oral CGRP receptor antagonist telcagepant. Headache 48 suppl 1 (2008) 7-8